Retatrutide Phase 3 results have placed Eli Lilly’s once-weekly triple agonist at the center of obesity research. The TRIUMPH program tested the investigational drug in thousands of adults, and the headline figures match levels once linked with bariatric surgery. This guide explains what each trial found, how safe the drug looked, and where regulators stand. It is written for researchers and curious readers who want clear facts without marketing hype.
Retatrutide Phase 3 Results at a Glance
The largest readout so far is TRIUMPH-1, an 80-week trial of 2,339 adults with obesity or overweight. On the highest 12 mg dose, participants lost an average of 28.3% of body weight, or 70.3 lb. A prespecified extension in people with severe obesity reached 30.3% at 104 weeks. These retatrutide Phase 3 results exceed earlier incretin trials, but comparisons across studies require caution because populations and methods differ.
How Retatrutide Phase 3 Results Relate to Its Mechanism
Retatrutide is a single molecule that activates three receptors: GIP, GLP-1 and glucagon. The first two are already targeted by tirzepatide and semaglutide. Glucagon activation is the new element, and researchers believe it may raise energy expenditure. The drug is given as a once-weekly injection in trials. It remains investigational, so it has no approved dose, label or prescribing route anywhere in the world today, whatever online sellers may claim.
Eli Lilly Phase 3 Retatrutide Program Explained
The TRIUMPH and TRANSCEND studies cover several patient groups. TRIUMPH-1 examines general obesity, TRIUMPH-2 adults with type 2 diabetes, TRIUMPH-3 people with cardiovascular disease, and TRIUMPH-4 knee osteoarthritis. Participants began at 2 mg weekly and stepped up every four weeks to 4, 9, or 12 mg. Each trial was randomized, double-blind and placebo-controlled, which strengthens the credibility of the retatrutide clinical trial data. Together, these studies form the evidence base for the retatrutide phase 3 results discussed below.
Retatrutide Phase 3 Results by Dose
The retatrutide phase 3 results by dose show a clear pattern. At 80 weeks, the 4 mg group lost 19.0%, the 9 mg group lost 25.9%, and the 12 mg group lost 28.3%. In the 12 mg arm, 45.3% of participants lost 30% or more of their body weight, and 65.3% fell below a BMI of 30. Waist circumference dropped by 24.1 cm, and blood pressure and cholesterol also improved.
Retatrutide Body Weight Reduction Over 104 Weeks
The 104-week extension in the retatrutide phase 3 results enrolled 532 participants with a baseline BMI of at least 35 who tolerated treatment. Those on 12 mg kept losing weight, finishing with an average of 85.0 lb, a 30.3% reduction. This retatrutide body weight reduction suggests that loss had not clearly plateaued at 80 weeks in this group. It applies only to people with severe obesity, so it should not be generalised to everyone.
Why Retatrutide Phase 3 Results Differ Between Reports
Some outlets quote lower averages, such as 25.0% at 12 mg. The gap most likely reflects the analysis method. Lilly reports an efficacy estimand, which covers people who stayed on treatment, and a treatment-regimen estimand, which includes everyone regardless of adherence. Neither is wrong. Any honest summary of retatrutide phase 3 results should name the method used and avoid mixing the two sets of figures. Our research peptide blog explains more trial terms in plain English.
Retatrutide Phase 3 Results Beyond TRIUMPH-1
Retatrutide phase 3 results extend well beyond general obesity. TRIUMPH-4 enrolled 445 adults with obesity and knee osteoarthritis. After 68 weeks, the 12 mg group lost 28.7% of body weight, and pain scores fell by up to 4.5 points. The retatrutide TRIUMPH-4 results also showed 12.0% of that group completely free of knee pain in a post hoc analysis, against 4.2% on placebo. Discontinuations due to side effects reached 18.2%.
Type 2 Diabetes and Cardiovascular Trials
Other retatrutide phase 3 results cover diabetes. In TRANSCEND-T2D-1, 537 adults with type 2 diabetes saw A1C fall by up to 2.0 percentage points over 40 weeks. TRIUMPH-2 later reported up to 20.8% weight loss at 80 weeks in adults with obesity and type 2 diabetes. TRIUMPH-3, in people with established cardiovascular disease, read out in July 2026. Lilly says these studies complete the data package needed for global regulatory submissions in obesity, knee pain and sleep apnoea.
Retatrutide Phase 3 Results on Safety and Side Effects
Safety is central to any reading of retatrutide phase 3 results. Side effects were mostly gastrointestinal and rose with dose, which is typical for incretin-based medicines. In TRIUMPH-1, nausea affected 42.4% on 12 mg versus 14.8% on placebo, diarrhoea 32.0% versus 13.5%, and vomiting 25.3% versus 4.8%. Discontinuation due to adverse events was 4.1% on 4 mg, 6.9% on 9 mg and 11.3% on 12 mg, against 4.9% on placebo.
What the Safety Data Cannot Yet Tell Us
Topline press releases are not peer-reviewed papers. Open questions include how long weight loss lasts after stopping treatment, how retatrutide compares directly with tirzepatide, and long-term cardiovascular and kidney outcomes. Higher discontinuation rates at 12 mg, including some for perceived excessive weight loss, also need careful interpretation. Wait for full publications before drawing firm conclusions from retatrutide phase 3 results, especially on rare side effects. Our FAQs cover common questions about research-use-only materials.
Are Retatrutide Phase 3 Results Enough for Approval?
Not yet. Strong retatrutide phase 3 results do not equal approval. Retatrutide remains investigational, and Lilly has said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. A filing is not an approval, and review typically takes 10 to 12 months. The FDA has also stated that retatrutide cannot be used in compounding under federal law. Products sold online as retatrutide are not approved medicines, and their contents are unverified.
Research Use and Where to Learn More
Axiom Labs UK supplies carefully sourced materials strictly for laboratory research, never for human consumption, veterinary use or medical use. For general background, explore research peptides UK or learn how the company works and which standards it follows. Comparing suppliers for professional laboratory work? Our guide to local suppliers of research peptides UK explains which quality checks, certificates and documents to look for before you order from any UK supplier.
Frequently Asked Questions
What do the retatrutide phase 3 results show for weight loss?
In TRIUMPH-1, adults taking the 12 mg dose lost an average of 28.3% of body weight, or 70.3 lb, after 80 weeks. The 9 mg dose produced 25.9% and the 4 mg dose 19.0%. A 104-week extension in people with severe obesity reached 30.3%. These retatrutide phase 3 results come from a randomised, double-blind, placebo-controlled trial of 2,339 adults without diabetes, so the evidence is strong, though full peer-reviewed data is still awaited.
Which side effects appeared in the retatrutide phase 3 results?
Gastrointestinal effects were most common and rose with dose. On 12 mg in TRIUMPH-1, nausea affected 42.4% of participants, diarrhoea 32.0%, constipation 26.1%, and vomiting 25.3%. Discontinuation due to adverse events was 11.3% on 12 mg against 4.9% on placebo. Mild to moderate dysesthesia, an altered skin sensation, was also reported, along with some upper respiratory and urinary tract infections.
Is retatrutide approved yet?
No. Retatrutide is still investigational. Eli Lilly has said it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027, and review usually takes 10 to 12 months. A filing is not an approval, and strong retatrutide phase 3 results do not change that. The FDA has also stated that retatrutide cannot be used in compounding, so products sold online as retatrutide are not approved medicines, and their contents are unverified.
How do retatrutide phase 3 results compare with tirzepatide and semaglutide?
Earlier trials of the highest trispeptide and semaglutide doses reported roughly 20% average weight loss after 72 weeks. Retatrutide reached 28.3% at 80 weeks on 12 mg in TRIUMPH-1. The trials differ in design, length and populations, so the comparison is only indirect. Only head-to-head studies can show whether retatrutide is truly superior to either medicine, and none of those results are available yet.
